A Visit to 中外製薬工業株式会社 Chugai’s Award-Winning Tokyo Facility: A Benchmark in Social Impact and Excellence
Mike Martin
A Message from the President and CEO, ISPE - In late May, I had the distinct pleasure of visiting 中外製薬工業株式会社 Chugai Pharmaceutical Manufacturing Co., Ltd.’s UK4 biological drug substance manufacturing facility in Tokyo, Japan—Category Winner of the 2024 ISPE Facility of the Year Awards (FOYA) in Social Impact. This visit was not only inspiring but also a powerful reminder of the innovation and dedication that define the future of pharmaceutical manufacturing.
From the moment we stepped into the facility, the attention to detail and quality of the finishes was immediately apparent. Every corridor, cleanroom, and workspace reflected a commitment to excellence. But what truly stood out was the professionalism and passion of the Chugai team—from the technical experts who guided us through the facility’s sustainable systems, to the general manager whose leadership was evident in every interaction.
Chugai Pharmaceutical Manufacturing Co., Ltd - Team
The Chugai team was visibly proud and excited to host our group of industry experts and ISPE leaders. Their hospitality was matched only by their enthusiasm to share the story behind the UK4 project—a facility designed under the visionary “Three Zeros for Sustainable Development” concept: zero halogenated hydrocarbons, zero natural gas, and zero CO₂ emissions in non-GMP areas.
In the entry lobby, visitors are greeted by a display of the FOYA trophy and a celebratory photo from the FOYA Banquet and Awards Celebration—symbols of a well-earned recognition. Winning the FOYA Category Award for Social Impact has brought Chugai global industry recognition, and they have embraced this honor by actively connecting peers to ISPE and supporting the growth of the ISPE brand.
What makes the FOYA award so prestigious is that it represents recognition by industry peers—executives and professionals who understand the challenges and triumphs of building world-class facilities. It’s a celebration of innovation, sustainability, and operational excellence.
If your organization is working on a facility that exemplifies these values, I strongly encourage you to submit it for FOYA consideration. The 2026 FOYA program will be open for submissions on 11 August. Applicants can submit their entries here. It’s more than an award—it’s a platform to inspire and elevate the entire industry. To stay connected with the latest in pharmaceutical engineering and facility innovation, follow ISPE on LinkedIn and consider joining ISPE as a member. It’s a community where excellence is shared, celebrated, and continuously redefined.
Congratulations again to Chugai Pharma Manufacturing Co., Ltd. for setting a new standard in sustainable facility design and for being such gracious hosts. Your work is a beacon for the future of our industry.
Join ISPE Today
Becoming a member of ISPE offers numerous benefits, including access to a vast network of professionals, exclusive training events, and valuable resources. As a member, you'll join more than 22,000 of your professional peers from over 120 countries in advancing solutions that lead to improved patient health. Membership provides access to 20+ complimentary ISPE Good Practice Guides, a robust library of on-demand training and e-learning resources, and much more. Learn more and consider joining today.
Established in 2005, the FOYA program recognizes state-of-the-art projects utilizing new, innovative technologies to improve the quality of products, reduce the cost of producing high-quality medicines, and demonstrate advances in project delivery. The FOYA program provides a platform for the pharmaceutical science and manufacturing industry to showcase its accomplishments in facility design, construction, and operation, while sharing the development of new applications of technology and cutting-edge approaches.
Bringing a wealth of experience and expertise to this role, Mike has a distinguished career spanning more than 35 years in the pharmaceutical industry. Most...
Building on the discussion in Part One about the need for standardization across research and development (R&D) and quality control (QC) laboratories, this second part of the series explores how laboratories can progress toward plug-and-play automation.
Pharma companies are currently experiencing unprecedented challenges as a result of external factors such as geopolitics, the adoption of new modalities, rapidly changing technologies including digital ones, and also regulatory changes. In order to overcome these challenges, the pharmaceutical industry must accelerate and embrace new technologies, approaches and thinking. Hence to grow and...
The 2026 ISPE Facilities of the Future Conference is set to take place 2–3 February in San Diego, California, USA. The conference will focus on the future of pharmaceutical manufacturing, with dedicated technical tracks on compliance and quality;...